Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nutrition
Published in: European Journal of Nutrition 1/2016

01-02-2016 | Original Contribution

The combination of resveratrol and quercetin enhances the individual effects of these molecules on triacylglycerol metabolism in white adipose tissue

Authors: Noemí Arias, M. Teresa Macarulla, Leixuri Aguirre, Iñaki Milton, María P. Portillo

Published in: European Journal of Nutrition | Issue 1/2016

Login to get access

Abstract

Purpose

The aim of this study was to analyze whether the combination of resveratrol and quercetin showed additive or synergic effects on body fat accumulation and triacylglycerol metabolism in adipose tissue from rats fed an obesogenic diet.

Methods

Rats were divided into four dietary groups: a control group and three groups each treated with either resveratrol (15 mg/kg/day; RSV), quercetin (30 mg/kg/day; Q), or both (15 mg resveratrol/kg/day and 30 mg quercetin/kg/day; RSV + Q) for 6 weeks. White adipose tissues from several anatomical locations were dissected. Serum parameters were analyzed by using commercial kits. The activities of fatty acid synthase and heparin-releasable lipoprotein lipase (HR-LPL) were measured using spectrophotometric and fluorimetric methods, and protein expression of acetyl-CoA carboxylase (ACC), adipose tissue triglyceride lipase (ATGL), and hormone-sensitive lipase (HSL) by western blot.

Results

The administration of either resveratrol or quercetin separately did not induce significant reductions in adipose tissue weights. By contrast, the combination of both molecules led to a significant reduction in all the fat depots analyzed. The percentage of reduction in each tissue was greater than the calculated additive effect. HR-LPL activity was reduced in RSV and RSV + Q groups. The activity of HSL was not modified. By contrast, ACC was inhibited and ATGL increased only by the combination of both polyphenols.

Conclusion

The results obtained demonstrate a synergistic effect between resveratrol and quercetin and suggest that when these molecules are combined, a great number of metabolic pathways involved in adipose tissue triacylglycerol accumulation are affected.
Literature
1.
Kelly T, Yang W, Chen CS, Reynolds K, He J (2008) Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond) 32:1431–1437CrossRef
2.
van Strien T, Koenders PG (2012) How do life style factors relate to general health and overweight? Appetite 58:265–270CrossRef
3.
van Vliet-Ostaptchouk JV, Snieder H, Lagou V (2012) Gene–lifestyle interactions in obesity. Curr Nutr Rep 1:184–196CrossRef
4.
Szkudelska K, Szkudelski T (2010) Resveratrol, obesity and diabetes. Eur J Pharmacol 635:1–8CrossRef
5.
Aguirre L, Fernández-Quintela A, Arias N, Portillo MP (2014) Resveratrol: anti-obesity mechanisms of action. Molecules 19:18632–18655CrossRef
6.
Dal-Pan A, Blanc S, Aujard F (2010) Resveratrol suppresses body mass gain in a seasonal non-human primate model of obesity. BMC Physiol 10:11CrossRef
7.
Jimenez-Gomez Y, Mattison JA, Pearson KJ et al (2013) Resveratrol improves adipose insulin signaling and reduces the inflammatory response in adipose tissue of rhesus monkeys on high-fat, high-sugar diet. Cell Metab 18:533–545CrossRef
8.
Panchal SK, Poudyal H, Brown L (2012) Quercetin ameliorates cardiovascular, hepatic, and metabolic changes in diet-induced metabolic syndrome in rats. J Nutr 142:1026–1032CrossRef
9.
Jung CH, Cho I, Ahn J, Jeon TI, Ha TY (2013) Quercetin reduces high-fat diet-induced fat accumulation in the liver by regulating lipid metabolism genes. Phytother Res 27:139–143CrossRef
10.
Yoshino J, Conte C, Fontana L et al (2012) Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab 16:658–664CrossRef
11.
Crandall JP, Oram V, Trandafirescu G et al (2012) Pilot study of resveratrol in older adults with impaired glucose tolerance. J Gerontol A Biol Sci Med Sci 67:1307–1312CrossRef
12.
Poulsen MM, Vestergaard PF, Clasen BF et al (2013) High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 62:1186–1195CrossRef
13.
Chachay VS, Macdonald GA, Martin JH et al (2014) Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 12(2092–2103):e2096
14.
Cho SJ, Jung UJ, Choi MS (2012) Differential effects of low-dose resveratrol on adiposity and hepatic steatosis in diet-induced obese mice. Br J Nutr 108:2166–2175CrossRef
15.
Gómez-Zorita S, Fernández-Quintela A, Macarulla MT et al (2012) Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. Br J Nutr 107:202–210CrossRef
16.
Timmers S, Konings E, Bilet L et al (2011) Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 14:612–622CrossRef
17.
Yang JY, Della-Fera MA, Rayalam S et al (2008) Enhanced inhibition of adipogenesis and induction of apoptosis in 3T3-L1 adipocytes with combinations of resveratrol and quercetin. Life Sci 82:1032–1039CrossRef
18.
Rayalam S, Della-Fera MA, Yang JY, Park HJ, Ambati S, Baile CA (2007) Resveratrol potentiates genistein’s antiadipogenic and proapoptotic effects in 3T3-L1 adipocytes. J Nutr 137:2668–2673
19.
Park HJ, Yang JY, Ambati S et al (2008) Combined effects of genistein, quercetin, and resveratrol in human and 3T3-L1 adipocytes. J Med Food 11:773–783CrossRef
20.
Herranz-López M, Fernández-Arroyo S, Pérez-Sanchez A et al (2012) Synergism of plant-derived polyphenols in adipogenesis: perspectives and implications. Phytomedicine 19:253–261CrossRef
21.
Langcake P, Pryce RJ (1976) The production of resveratrol by Vitis vinifera and other members of the Vitaceae as a response to infection or injury. Physiol Plant Pathol 9:77–86CrossRef
22.
Somerset SM, Johannot L (2008) Dietary flavonoid sources in Australian adults. Nutr Cancer 60:442–449CrossRef
23.
Macarulla MT, Alberdi G, Gómez S et al (2009) Effects of different doses of resveratrol on body fat and serum parameters in rats fed a hypercaloric diet. J Physiol Biochem 65:369–376CrossRef
24.
Del Prado M, Hernandez-Montes H, Villalpando S (1994) Characterization of a fluorometric method for lipoprotein lipase. Arch Med Res 25:331–335
25.
Miranda J, Churruca I, Fernández-Quintela A et al (2009) Weak effect of trans-10, cis-12-conjugated linoleic acid on body fat accumulation in adult hamsters. Br J Nutr 102:1583–1589CrossRef
26.
Alberdi G, Rodríguez VM, Miranda J et al (2011) Changes in white adipose tissue metabolism induced by resveratrol in rats. Nutr Metab (Lond) 8:29CrossRef
27.
Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254CrossRef
28.
Carpéné C, Gomez-Zorita S, Gupta R et al (2014) Combination of low dose of the anti-adipogenic agents resveratrol and phenelzine in drinking water is not sufficient to prevent obesity in very-high-fat diet-fed mice. Eur J Nutr 53:1625–1635CrossRef
29.
Arias N, Macarulla MT, Aguirre L et al (2011) The combination of resveratrol and conjugated linoleic acid is not useful in preventing obesity. J Physiol Biochem 67:471–477CrossRef
30.
Arias N, Miranda J, Macarulla MT et al (2014) The combination of resveratrol and conjugated linoleic acid attenuates the individual effects of these molecules on triacylglycerol metabolism in adipose tissue. Eur J Nutr 53:575–582CrossRef
31.
Lagouge M, Argmann C, Gerhart-Hines Z et al (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127:1109–1122CrossRef
32.
Rivera L, Morón R, Sánchez M, Zarzuelo A, Galisteo M (2008) Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats. Obesity (Silver Spring) 16:2081–2087CrossRef
33.
Shang J, Chen LL, Xiao FX, Sun H, Ding HC, Xiao H (2008) Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacol Sin 29:698–706CrossRef
34.
Kim S, Jin Y, Choi Y, Park T (2011) Resveratrol exerts anti-obesity effects via mechanisms involving down-regulation of adipogenic and inflammatory processes in mice. Biochem Pharmacol 81:1343–1351CrossRef
35.
Kobori M, Masumoto S, Akimoto Y, Oike H (2011) Chronic dietary intake of quercetin alleviates hepatic fat accumulation associated with consumption of a Western-style diet in C57/BL6J mice. Mol Nutr Food Res 55:530–540CrossRef
36.
Arias N, Macarulla MT, Aguirre L, Martínez-Castaño MG, Portillo MP (2014) Quercetin can reduce insulin resistance without decreasing adipose tissue and skeletal muscle fat accumulation. Genes Nutr 9:361CrossRef
37.
Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited. FASEB J 22:659–661CrossRef
38.
Timmers S, Auwerx J, Schrauwen P (2012) The journey of resveratrol from yeast to human. Aging (Albany NY) 4:146–158
39.
de Ligt M, Timmers S, Schrauwen P (2014) Resveratrol and obesity: Can resveratrol relieve metabolic disturbances? Biochim Biophys Acta (in press)
40.
National Institutes of Health (NIH) in USA. ClinicalTrials.gov
41.
Rayalam S, Della-Fera MA, Ambati S, Boyan B, Baile CA (2007) Enhanced effects of guggulsterone plus 1,25(OH)2D3 on 3T3-L1 adipocytes. Biochem Biophys Res Commun 364:450–456CrossRef
42.
Panchal SK, Brown L (2011) Rodent models for metabolic syndrome research. J Biomed Biotechnol 2011:351982CrossRef
43.
Babacanoglu C, Yildirim N, Sadi G, Pektas MB, Akar F (2013) Resveratrol prevents high-fructose corn syrup-induced vascular insulin resistance and dysfunction in rats. Food Chem Toxicol 60:160–167CrossRef
44.
Vang O, Ahmad N, Baile CA et al (2011) What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS ONE 6:e19881CrossRef
45.
Wang S, Moustaid-Moussa N, Chen L et al (2014) Novel insights of dietary polyphenols and obesity. J Nutr Biochem 25:1–18CrossRef
46.
Lane MD, Moss J, Polakis SE (1974) Acetyl coenzyme A carboxylase. Curr Top Cell Regul 8:139–195CrossRef
47.
Miyoshi H, Perfield JW, Obin MS, Greenberg AS (2008) Adipose triglyceride lipase regulates basal lipolysis and lipid droplet size in adipocytes. J Cell Biochem 105:1430–1436CrossRef
48.
Watt M, Steinberg G (2008) Regulation and function of triacylglycerol lipases in cellular metabolism. Biochem J 414:313–325CrossRef
49.
Haemmerle G, Lass A, Zimmermann R et al (2006) Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science 312:734–737CrossRef
50.
Duncan RE, Ahmadian M, Jaworski K, Sarkadi-Nagy E, Sul HS (2007) Regulation of lipolysis in adipocytes. Annu Rev Nutr 27:79–101CrossRef
51.
Zimmermann R, Strauss JG, Haemmerle G et al (2004) Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. Science 306:1383–1386CrossRef
Metadata
Title
The combination of resveratrol and quercetin enhances the individual effects of these molecules on triacylglycerol metabolism in white adipose tissue
Authors
Noemí Arias
M. Teresa Macarulla
Leixuri Aguirre
Iñaki Milton
María P. Portillo
Publication date
01-02-2016
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nutrition / Issue 1/2016
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI
https://doi.org/10.1007/s00394-015-0854-9

Other articles of this Issue 1/2016

European Journal of Nutrition 1/2016 Go to the issue

Original Contribution

Vitamin D metabolites and fibroblast growth factor-23 in patients with left ventricular assist device implants: association with stroke and mortality risk

Original Contribution

FTO gene variation, macronutrient intake and coronary heart disease risk: a gene–diet interaction analysis

Original Contribution

Gestational dietary patterns are not associated with blood pressure changes during pregnancy and early postpartum in a Brazilian prospective cohort

Original Contribution

Association of magnesium in serum and urine with carotid intima-media thickness and serum lipids in middle-aged and elderly Chinese: a community-based cross-sectional study

Original Contribution

A dose–response study of vitamin D3 supplementation in healthy Chinese: a 5-arm randomized, placebo-controlled trial

Original Contribution

Kefir drink leads to a similar weight loss, compared with milk, in a dairy-rich non-energy-restricted diet in overweight or obese premenopausal women: a randomized controlled trial
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits